Novel coronavirus self inspection tool was launched yesterday on the official website of the Healthcare based on Microsoft's Healthcare Bot service. It can assess people's symptoms and risk factors and help them make medical decisions. Besides,Microsoft 公司总部所在地：美国 主要业务：软件 andAdaptive BioTechnologiesCooperate to study how novel coronavirus can be handled by human immune system.
Adaptive biotechnology is a Seattle based start-up company with a broad mission to understand the response of the human immune system to disease and ultimately develop an "immunoassay tool" that allows patients to be screened for infectious diseases, cancer and autoimmune problems once or twice a year. But it may be the next decade to achieve such research and development goals.
The cooperation with Microsoft will promote the research and commercial work of vaccines. In their collaboration, they will map a large-scale population adaptive immune response to the disease to study the coronavirus. If the characteristics of immune response are found, it may promote the diagnosis, treatment and prevention of the disease solutions, thus increasing the existing research work.
Also, through open data access, Microsoft and Adaptive are free to researchers, public health officials or organizations around the world.
Adaptive BioTechnologies said novel coronavirus infected persons or rehabilitated blood samples would be collected from next month to start a virtual clinical study. A DNA sequencer from Illumina will be used to sequence immune cell receptors. All data collected around the immune response will be uploaded to an open data access portal for researchers to use.
Microsoft will provide its cloud computing and machine learning technologies to help understand these samples. Microsoft Research Director Peter Lee (Peter Lee) said the two companies have been working together for years to better understand the human immune system, using their technology to link all T cell receptors to the antigens they attack.